| scholarly article | Q13442814 |
| P356 | DOI | 10.1001/ARCHSURG.1989.01410010027005 |
| P698 | PubMed publication ID | 2910244 |
| P50 | author | Aman U Buzdar | Q114440916 |
| P2093 | author name string | Smith TL | |
| Hortobagyi GN | |||
| Balch CM | |||
| Kau SW | |||
| McCready DR | |||
| P433 | issue | 1 | |
| P921 | main subject | lymph node | Q170758 |
| chemotherapy | Q974135 | ||
| P304 | page(s) | 21-25 | |
| P577 | publication date | 1989-01-01 | |
| P1433 | published in | Archives of Surgery | Q15764793 |
| P1476 | title | The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer | |
| P478 | volume | 124 |
| Q40824121 | 18-FDG imaging in breast cancer |
| Q37158568 | A pilot study to assess the feasibility of evaluation of markers of response to chemotherapy at one day & 21 days after first cycle of chemotherapy in carcinoma of breast: a prospective non-randomized observational study |
| Q50511302 | Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors. |
| Q35585792 | Advances in breast cancer detection and management |
| Q43785981 | Biological considerations in locally advanced breast cancer treated with anthracycline-based neoadjuvant chemotherapy: thymidine labelling index is an independent indicator of clinical outcome |
| Q71475799 | Breast surgery after neoadjuvant treatment. Is it necessary? |
| Q44267351 | Clinical significance of axillary microresiduals after neoadjuvant chemotherapy in breast cancer patients with cytologically proven metastases |
| Q35180757 | Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer |
| Q47924052 | Diagnosis and Management of Inflammatory Breast Cancer |
| Q46757098 | Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC). |
| Q70822193 | Endocrine and cytotoxic therapies for the management of advanced local breast cancer. Current clinical investigation |
| Q37607969 | Evaluation of Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Experience in a Single Institution over a 10-Year Period |
| Q35194725 | Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy |
| Q28270514 | Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944) |
| Q45946724 | Fine-needle aspiration cytology in locally advanced breast adenocarcinoma: a case with complete response to preoperative chemotherapy in association with granulomatous inflammatory reaction. |
| Q77184884 | Gamma emission imaging in the management of breast disorders |
| Q77983563 | Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy |
| Q71022873 | Inflammatory breast cancer |
| Q47956853 | Inflammatory breast carcinoma: a community hospital experience |
| Q36414392 | Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer |
| Q35052273 | Lessons learned from the initial 100 patient experience with sentinel lymph node mapping in the evaluation of breast cancer. |
| Q33654588 | Locally advanced breast cancer |
| Q71022865 | Locally advanced noninflammatory breast cancer |
| Q53964484 | Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer. |
| Q41110592 | Lymph node status in inflammatory breast cancer. |
| Q40657320 | Management of locally advanced carcinoma of the breast. I. Noninflammatory. |
| Q35603892 | Management of patients with locally advanced breast cancer |
| Q36135126 | Mathematical modelling of tumour response in primary breast cancer |
| Q77224816 | Neoadjuvant chemotherapy in the treatment of stage II and III breast cancer |
| Q33854991 | Neoadjuvant chemotherapy in women with invasive breast carcinoma: conceptual basis and fundamental surgical issues |
| Q35782342 | Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes - what does it all mean? |
| Q90412921 | P-Glycoprotein Expression in Indian Breast Cancer Patients with Reference to Molecular Subtypes and Response to Anthracycline-Based Chemotherapy-a Prospective Clinical Study from a Developing Country |
| Q53810159 | P-glycoprotein: the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer. |
| Q46848282 | Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer. |
| Q35948773 | Predictors of pathological complete response to neoadjuvant chemotherapy in stage II and III breast cancer: The impact of chemotherapeutic regimen |
| Q77357017 | Primary chemotherapy in breast cancer |
| Q77713858 | Primary chemotherapy: a better overall therapeutic option for patients with breast cancer |
| Q35782175 | Prognostic factors. Stage and receptor status in breast cancer |
| Q36291690 | Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer |
| Q36621469 | Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer |
| Q44199263 | Prognostic value of residual node involvement in operable breast cancer after induction chemotherapy |
| Q27304609 | Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration |
| Q77985953 | Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer |
| Q77931167 | Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer |
| Q81241381 | Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival |
| Q53849848 | Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer. |
| Q33972653 | Role of axillary surgery in early breast cancer: review of the current evidence |
| Q24815650 | Role of p-glycoprotein expression in predicting response to neoadjuvant chemotherapy in breast cancer--a prospective clinical study |
| Q92918597 | Second-harmonic generation directionality is associated with neoadjuvant chemotherapy response in breast cancer core needle biopsies |
| Q50493807 | Sentinel node biopsy performed before preoperative chemotherapy for axillary lymph node staging in breast cancer. |
| Q40546057 | Sequential High-Dose Alkylating Therapy and Stem Cell Support for High-Risk Stage III Breast Cancer |
| Q33412047 | Sixteen years follow-up results of a randomized phase II trial of neoadjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) compared with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in stage III breast cancer: GOCS experience |
| Q47346611 | Size of residual lymph node metastasis after neoadjuvant chemotherapy in locally advanced breast cancer patients is prognostic |
| Q77125624 | Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose |
| Q38552975 | Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group |
| Q37244111 | State of the art of neoadjuvant chemotherapy in breast cancer: rationale, results and recent developments |
| Q40931740 | Surgical and medical management of local-regional treatment failures in advanced primary breast cancer. |
| Q36135796 | Systemic treatment for locally advanced breast cancer: what we still need to learn after a decade of multimodality clinical trials |
| Q36838312 | Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy |
| Q34141866 | The evidence-based use of induction chemotherapy in breast cancer |
| Q33779190 | The role of radiation therapy for primary breast cancer |
| Q77357189 | Treatment implications of a positive sentinel lymph node biopsy for patients with early-stage breast carcinoma |
| Q33986198 | Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer |
| Q37121648 | Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer |
| Q36738511 | What is the burden of axillary disease after neoadjuvant therapy in women with locally advanced breast cancer? |
Search more.